German cannabis reimbursement: top court declines patient appeal

NewsGermany

By Spliff NewsroomPublished 3 November 2026 at 14:32·3 min read

Germany's Federal Constitutional Court in Karlsruhe has declined to hear a patient's complaint over the end of German cannabis reimbursement for dried flower, according to Business of Cannabis. The refusal came the week before 2 November 2026 and sends patients back to lower courts.

The court found the complaint inadmissible, according to Business of Cannabis. It ruled that the case had no fundamental constitutional importance. It also held that the patient was not directly affected in the constitutional sense.

The judges pointed to the principle of subsidiarity. In practice, a patient must exhaust the lower courts before the constitutional court can step in.

What the reimbursement change involved

Dried cannabis flower used to be reimbursed by statutory health insurance (GKV) under Article 31(6) of the German social code (SGB V). A cost-cutting law, the GKV-Beitragssatzstabilisierungsgesetz, removed flower from that coverage on 30 July 2026. About 65,000 patients are reported to have been affected.

Before the amendments, some patients had received open-ended reimbursement approvals. For background on the wider German picture, see our piece on Germany’s cannabis legalisation and offence figures.

Social courts reach different conclusions

The Social Court of Frankfurt ruled on 21 August 2026 that removing flower from the code simply ends the reimbursement claim. On 16 September 2026, the Social Court of Leipzig reached the same view for a patient reimbursed since 2018.

The Social Court of Landshut went the other way. It ordered reimbursement to continue while a challenge is reviewed, for a dialysis patient reimbursed since 2018. A Dresden court reportedly made a similar ruling, but Business of Cannabis could not verify it independently.

The law does not clearly define any transitional protection. That gap explains why courts read it differently.

Collective complaint still being prepared

The Arbeitsgemeinschaft Cannabis als Medizin (ACM) and lawyer Oliver Tolmein are preparing a collective-style constitutional complaint for a wider group of patients. It has not yet been filed. One patient’s appeal at the Saxony higher social court also remains pending.

A final national answer could eventually come from the Federal Social Court in Kassel. Cases there typically take three to five years from filing to a binding judgment, and often longer.

Pharmacy insolvency and Bundesrat vote

The specialist pharmacy Lux 99 in Hürth filed for insolvency on 24 October 2026 and blamed the GKV amendments. On 15 October 2026, the Bundestag approved the emergency care reform in third reading, with twelve amendments to the GKV savings bill.

One amendment eases the six-month trial requirement for finished cannabis-based medicines for new patients. It limits the rule to indications where an authorised cannabis-containing medicine actually exists, and leaves the duration to the doctor. It did not restore flower reimbursement. The Bundesrat, which represents the 16 states, is expected to deliberate on 20 November 2026.

What this means for you

If you live in Germany and rely on prescribed flower, the situation could vary depending on which court covers your case. Outcomes so far are contradictory, so nothing suggests a single answer soon. This is not legal advice; a doctor or a specialist lawyer is the right contact for your own situation.

For readers elsewhere in Europe, there is no direct consequence. The story shows how fast medical cannabis rules can shift. If you are browsing legal CBD products, our CBD flower collection is a starting point, and the Spain weed law guide covers another market.

Image created with AI